Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to estimate the relative risk of a persistent decline in FEV1 exceeding 20% from baseline among subjects with diabetes randomized to Exubera as compared with those not randomized to Exubera. For both treatment groups, a persistent decline in FEV1 exceeding 20% from baseline is defined as an observed decline in FEV1 exceeding 20% from baseline, 3 months after a confirmed decline in FEV1 exceeding 20% from baseline.
Critère d'inclusion
- Diabetes Mellitus Type I and Type II